Submitted by Anonymous (not verified) on 12 March 2025 - 16:30
Opinion/decision on a Paediatric investigation plan (PIP): RoActemra, tocilizumab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Infections and infestations, PIP number: P/0028/2024
Source: